11月12日，回盛生物盘中下跌2.03%，截至13:28，报21.70元/股，成交7294.51万元，换手率1.65%，总 市值43.91亿元。 资料显示，武汉回盛生物科技股份有限公司位于湖北省武汉市武昌区中华路1号，成立日期2002年1月25 日，上市日期2020年8月24日，公司主营业务涉及主要从事兽用药品(包括化药制剂、原料药、中药制 剂)、饲料及添加剂的研发、生产和销售。主营业务收入构成为：兽用原料药及制剂93.56%，其他 6.44%。 回盛生物所属申万行业为：农林牧渔-动物保健Ⅱ-动物保健Ⅲ。所属概念板块包括：小盘、融资融券、 饲料、原料药、合成生物等。 截至9月30日，回盛生物股东户数2.12万，较上期减少10.03%；人均流通股9566股，较上期增加 11.15%。2025年1月-9月，回盛生物实现营业收入12.60亿元，同比增长58.92%；归母净利润1.88亿元， 同比增长494.28%。 分红方面，回盛生物A股上市后累计派现2.36亿元。近三年，累计派现1.35亿元。 责任编辑：小浪快报 资金流向方面，主力资金净流出392.34万元，特大单买入380.37万元，占比5.21%，卖出210 ...

Core Viewpoint - The company, Huisheng Biological, reported significant growth in revenue and net profit for the first three quarters of the year, driven by increased product sales despite challenges in the swine breeding industry [1][2] Financial Performance - Revenue for the first three quarters reached approximately 1.26 billion yuan, a year-on-year increase of 58.92% [1] - Net profit attributable to shareholders was about 188 million yuan, up 494.28% year-on-year [1] - In Q3 alone, revenue was 437 million yuan, reflecting a 22.76% increase year-on-year, while net profit soared to 70.72 million yuan, a staggering 1575.79% increase [1] Business Strategy - The implementation of a raw material and formulation integration strategy has significantly enhanced the company's competitiveness and profitability [2] - The raw material business saw substantial revenue growth compared to the previous year, indicating successful strategic execution [2] Market Development - The company is focusing on innovation in microbial fermentation to improve production efficiency and product quality, while also expanding its domestic and international market presence [2] - The overseas market is primarily driven by raw material exports, with formulation exports still in the exploratory phase [2] Capacity Expansion - The company announced plans to invest 170 million yuan in upgrading its veterinary raw material production lines, aimed at enhancing production capacity and energy efficiency [2] - The upgrade will involve the introduction of high-efficiency, automated equipment and will focus on reducing waste and improving resource utilization [2]

Group 1 - The core viewpoint of the news is that Huisheng Biological has experienced fluctuations in its stock price and trading volume, with a significant increase in stock price year-to-date, but recent declines in the short term [1] - As of October 16, Huisheng Biological's stock price was 20.92 yuan per share, with a market capitalization of 4.233 billion yuan and a trading volume of 80.2648 million yuan [1] - The company has seen a net outflow of main funds amounting to 2.2558 million yuan, with large orders showing a mixed buying and selling pattern [1] Group 2 - Huisheng Biological operates primarily in the veterinary medicine sector, with 93.56% of its revenue coming from veterinary raw materials and formulations [1] - As of June 30, the number of shareholders increased by 65.21% to 23,500, while the average number of circulating shares per person decreased by 28.44% [2] - For the first half of 2025, Huisheng Biological reported a revenue of 822 million yuan, representing a year-on-year growth of 88.45%, and a net profit attributable to shareholders of 117 million yuan, up 325.88% year-on-year [2] Group 3 - Since its A-share listing, Huisheng Biological has distributed a total of 236 million yuan in dividends, with 135 million yuan distributed over the past three years [3]

Core Viewpoint - The company reported significant growth in revenue and net profit for the first half of 2025, indicating a recovery in the animal health sector after a period of decline [1][2]. Financial Performance - The company's revenue for the first half of 2025 was approximately 822 million yuan, an increase of 88.45% year-on-year [1]. - The net profit attributable to shareholders was about 117 million yuan, marking a turnaround from losses with a year-on-year growth of 325.88% [1]. - In Q1 2025, revenue grew by 92.96% and net profit increased by 371.23% [2]. Segment Analysis - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1]. - Sales revenue from veterinary raw materials surged by 199.01% year-on-year, with a gross margin improvement of 27.14% [1]. Investment and Expansion Plans - The company plans to invest 170 million yuan in upgrading its veterinary raw material production lines, which will enhance efficiency and reduce costs [2]. - The upgrade will include the introduction of high-efficiency, automated equipment and the addition of fermentation product production lines [2]. Strategic Focus - The company is focusing on vertical integration in the raw material drug industry and horizontal expansion into pet, poultry, ruminant, and aquaculture sectors [3]. - The strategy includes developing new veterinary drugs, optimizing product performance, and expanding into international markets to mitigate domestic cyclical impacts [3].

Core Insights - Nanyang, located in southern Henan, has a strong foundation for biomass manufacturing and energy conversion, with over 30 million tons of biomass raw materials produced annually, including over 10 million tons of crop straw and over 10 million livestock [1] - The "2025 Nanyang Synthetic Biology Industry Conference" established the "Central Plains Synthetic Biology Industry-Academia-Research Innovation Alliance" and released the "Biomanufacturing Pilot Zone Action Plan" 1.0, aiming to develop a trillion-level synthetic biology industry cluster [1][5] - The synthetic biology industry in Nanyang has a solid demand foundation, with Muyuan, a leading pig farming company, driving the development of synthetic biology technology through cost reduction initiatives [1][3] Company Developments - In 2023, Muyuan partnered with Westlake University to establish the Nanyang Westlake Muyuan Synthetic Biology Research Institute and Muyuan Laboratory, focusing on producing small amino acids through synthetic biology technology [2] - Muyuan's production of synthetic biological products has commenced, with an annual output of 30,000 tons, promoting the industrialization of amino acid biosynthesis technology [2] Financial Performance - Muyuan's 2025 mid-year performance forecast indicates a net profit of 10.2 billion to 10.7 billion yuan, representing a year-on-year increase of 1129.97% to 1190.26% [3] - The company expects a non-net profit of 10.6 billion to 11.1 billion yuan, reflecting a year-on-year growth of 882.95% to 929.31% [3] - The significant increase in performance is attributed to a rise in pig output and a decrease in breeding costs, with the total cost of pig farming dropping from 13.1 yuan/kg at the beginning of the year to below 12.1 yuan/kg by June [3] Industry Trends - The application of synthetic biology technology in the livestock industry is just a small part of its potential, with future applications expected in materials, agricultural technology, food, and healthcare [4] - Nanyang is developing a comprehensive industrial support service system, focusing on energy integration and logistics to further reduce production costs [4][6] - The region aims to focus on key areas such as feed amino acid substitution, biomedicine, and bio-based materials, driving the entire industry chain upgrade through breakthroughs in synthetic biology [6]